Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of “Buy” from Brokerages

Vor Biopharma Inc. (NYSE:VOR) has earned a consensus recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have covered the stock in the last year is $11.36.

VOR has been the subject of several research analyst reports. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Vor Biopharma in a research note on Monday, December 9th. HC Wainwright restated a “buy” rating and issued a $17.50 target price on shares of Vor Biopharma in a research report on Tuesday, December 10th. Robert W. Baird decreased their price target on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research note on Tuesday, December 10th.

Vor Biopharma Price Performance

Shares of NYSE VOR opened at $1.37 on Friday. The business has a 50-day moving average of $1.02 and a 200-day moving average of $0.91. Vor Biopharma has a 12 month low of $0.63 and a 12 month high of $2.59.

Vor Biopharma (NYSE:VOR) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.40) EPS for the quarter, hitting analysts’ consensus estimates of ($0.40). Analysts predict that Vor Biopharma will post -1.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in VOR. Hsbc Holdings PLC boosted its position in Vor Biopharma by 177.0% during the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after buying an additional 31,333 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Vor Biopharma during the second quarter valued at about $53,000. Rosalind Advisors Inc. purchased a new stake in shares of Vor Biopharma during the third quarter worth about $54,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vor Biopharma in the second quarter worth about $63,000. Finally, Acadian Asset Management LLC increased its holdings in Vor Biopharma by 51.4% during the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock valued at $79,000 after purchasing an additional 27,597 shares during the period. 97.29% of the stock is owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.